Kartogenin_product_DataBase

Bioactivity

Kartogenin (KGN) is an inducer of differentiation of human mesenchymal stem cells into chondrocytes, with an EC50 of 100 nM. Kartogenin binds filamin A, disrupts its interaction with the transcription factor core-binding factor β subunit (CBFβ), and induces chondrogenesis by regulating the CBFβ-RUNX1 transcriptional program. Kartogenin can be used for the research of osteoarthritis (OA)[1][2].

Invitro

Kartogenin (50-5000 nM; 2 weeks) induces the chondrogenetic differentiation of the BMSCs in a concentration-dependent manner[2].Kartogenin (100 nM; 72 h) induces chondrocyte nodule formation in primary hMSCs[1].Kartogenin (10 nM-10 μM; 72 h) increases chondrocyte-specific gene expression in hMSCs[1].Kartogenin (0.12-10 μM; 48 h) inhibits nitric oxide (NO) and glycosaminoglycan (GAG) release induced by cytokines in primary bovine articular chondrocytes[1].

In Vivo

Kartogenin (10 μM in 4μL of saline; i.a. on days 7 and 21) promotes cartilag erepair in collagenase VII-induced OA models in mice[1].

Name

Kartogenin

CAS

4727-31-5

Formula

C20H15NO3

Molar Mass

317.34

Appearance

Solid

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Reference

[1]. Johnson K, et, al. A stem cell-based approach to cartilage repair. Science. 2012 May 11;336(6082):717-21. [2]. Liu F, et, al. A novel kartogenin-platelet-rich plasma gel enhances chondrogenesis of bone marrow mesenchymal stem cells in vitro and promotes wounded meniscus healing in vivo. Stem Cell Res Ther. 2019 Jul 8;10(1):201.

PeptideDB

Kartogenin

CAS: 4727-31-5 F: C20H15NO3 W: 317.34